"It appears that infusions of targeted T cells have boosted the immune system to create a more efficient tumor killing machine within the patient's body," he said. "Although the median survival rate for all patients remains undefined, survival rates for the HER2 (0-2+) cohort is 21.3 months." He said that the immunotherapy may be vaccinating the patient's immune system to their own tumors. This is encouraging given that the tumor burden was high in the majority of women who had failed other therapies and the prognosis is poor.
In addition to Dr. Lum, abstract authors include: Zaid Al-Kadhimi, M.D., Associate Director of Immunotherapy, Karmanos Cancer Institute; Cassara Skuba, B.S., Supervisor of Cell Processing Facility, Karmanos Cancer Institute; Rebecca Sandborg, Ph.D., Karmanos Cancer Institute; Ritesh Rathore, M.D., Chief of Hematology/Oncology, Assistant Professor of Medicine, Boston University, Roger Williams Hospital, Providence, RI; Qin Liu, Ph.D., Assistant Professor of Medicine, University of Massachusetts, Worcester, MA; and Co-Leaders of the Karmanos Cancer Center BMT Multidisciplinary team Voravit Ratanatharathorn, M.D. and Joseph Uberti, M.D., Ph.D.
The Phase I Clinical Trial was supported by a National Cancer Institute ROI CA92344 grant, a translational grant from the Leukemia & Lymphoma Society Michigan Life Science Grant, funds from Roger Williams Hospital, Providence RI and funds from the Karmanos Cancer Institute.
The Barbara Ann Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute in Detroit is one of 41
National Cancer Institute (NCI)-designated
|SOURCE The Barbara Ann Karmanos Cancer Institute|
Copyright©2008 PR Newswire.
All rights reserved